EVOLENT HEALTH INC
NYSE: EVH (Evolent Health, Inc)
Kemas kini terakhir: 1 jam lalu7.64
-0.06 (-0.78%)
| Penutupan Terdahulu | 7.70 |
| Buka | 7.66 |
| Jumlah Dagangan | 1,327,325 |
| Purata Dagangan (3B) | 2,470,996 |
| Modal Pasaran | 896,936,000 |
| Harga / Pendapatan (P/E Ke hadapan) | 23.42 |
| Harga / Jualan (P/S) | 0.440 |
| Harga / Buku (P/B) | 1.15 |
| Julat 52 Minggu | |
| Tarikh Pendapatan | 6 Aug 2025 - 11 Aug 2025 |
| Margin Keuntungan | -2.41% |
| Margin Operasi (TTM) | -0.09% |
| EPS Cair (TTM) | -0.810 |
| Pertumbuhan Hasil Suku Tahunan (YOY) | 16.30% |
| Jumlah Hutang/Ekuiti (D/E MRQ) | 59.90% |
| Nisbah Semasa (MRQ) | 0.850 |
| Aliran Tunai Operasi (OCF TTM) | 18.77 M |
| Aliran Tunai Bebas Leveraj (LFCF TTM) | -41.00 M |
| Pulangan Atas Aset (ROA TTM) | 0.06% |
| Pulangan Atas Ekuiti (ROE TTM) | -5.06% |
Arah Aliran Pasaran
| Jangka Pendek | Jangka Sederhana | ||
| Industri | Health Information Services (US) | Menurun | Bercampur |
| Health Information Services (Global) | Menurun | Bercampur | |
| Stok | Evolent Health, Inc | Menurun | Menurun |
AISkor Stockmoo
| Konsensus Penganalisis | 1.0 |
| Aktiviti Orang Dalam | NA |
| Volatiliti Harga | 1.5 |
| Purata Bergerak Teknikal | 2.5 |
| Osilator Teknikal | -2.5 |
| Purata | 0.63 |
|
Evolent Health Inc is engaged in healthcare delivery and payment. The company supports health systems and physician organizations in their migration toward value-based care and population health management. It provides specialty care management services in oncology, cardiology, musculoskeletal markets and holistic total cost of care management along with an integrated platform for health plan administration and value-based business infrastructure under one go to market package. The primary solutions provided by the company include specialty care management services, total cost of care management, and administrative services. |
|
| Sektor | Healthcare |
| Industri | Health Information Services |
| Gaya Pelaburan | Small Core |
| % Dimiliki oleh Orang Dalam | 1.24% |
| % Dimiliki oleh Institusi | 105.46% |
Pemilikan
| Nama | Tarikh | Syer Dipegang |
|---|---|---|
| Cadian Capital Management, Lp | 31 Mar 2025 | 10,794,606 |
| Engaged Capital Llc | 31 Mar 2025 | 5,179,468 |
| Rock Springs Capital Management Lp | 31 Mar 2025 | 2,695,700 |
| Julat 52 Minggu | ||
| Julat Harga Sasaran | ||
| Tinggi | 15.00 (Needham, 96.34%) | Beli |
| 15.00 (UBS, 96.34%) | Beli | |
| Median | 14.00 (83.25%) | |
| Rendah | 12.00 (JP Morgan, 57.07%) | Beli |
| Purata | 13.80 (80.63%) | |
| Jumlah | 5 Beli | |
| Harga Purata @ Panggilan | 9.33 | |
| Syarikat | Tarikh | Harga Sasaran | Panggilan | Harga @ Panggilan |
|---|---|---|---|---|
| Needham | 13 May 2025 | 15.00 (96.34%) | Beli | 9.27 |
| UBS | 09 May 2025 | 15.00 (96.34%) | Beli | 9.05 |
| JMP Securities | 28 Apr 2025 | 13.00 (70.16%) | Beli | 9.34 |
| Truist Securities | 10 Apr 2025 | 14.00 (83.25%) | Beli | 9.89 |
| JP Morgan | 10 Mar 2025 | 12.00 (57.07%) | Beli | 9.10 |
Tiada data dalam julat masa ini.
| Tarikh | Jenis | Butiran |
|---|---|---|
| 08 May 2025 | Pengumuman | Evolent Announces First Quarter 2025 Results |
| 22 Apr 2025 | Pengumuman | Evolent names Shawn Guertin as new independent nominee for election to its Board of Directors |
| 15 Apr 2025 | Pengumuman | Evolent program achieves 20% reduction in use of low-value oncology regimens |
| 10 Apr 2025 | Pengumuman | Evolent To Release First Quarter 2025 Financial Results on Thursday, May 8, 2025 |
| 10 Apr 2025 | Pengumuman | Evolent To Release First Quarter 2025 Financial Results on Thursday, May 8, 2025 |
| 11 Mar 2025 | Pengumuman | Define Ventures Appoints Carolyn Magill as Venture Partner |
Tahap sokongan, rintangan dan garis aliran yang dibentangkan telah dihasilkan oleh model kecerdasan buatan (AI) dan harus ditafsirkan dengan berhati-hati.
Portfolio
| Keuntungan Nyata | - |
| Keuntungan Tidak Nyata | - |
| Dividen Diterima 2025 | - |
| Jumlah Untung | - |
| Pulangan Purata | - |
| Kuantiti (Beli) | - |
| Purata Harga (Beli) | - |
| Kuantiti (Jual) | - |
| Purata Harga (Jual) | - |